Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)

Pyxis Oncology (PYXS) announced presentations on micvotabart pelidotin (MICVO) at the EORTC-NCI-AACR Symposium. The company will present a Phase 1 study on MICVO monotherapy for recurrent/metastatic head and neck cancer, and two posters on preclinical research. MICVO targets extradomain-B of fibronectin and has received FDA Fast Track Designation.

Pyxis Oncology (PYXS) closed a $110M public offering, with potential total proceeds of $282.6M if warrants are exercised. Proceeds will fund clinical trials for MICVO, its lead drug. The company also terminated its at-the-market offering, freeing up registration capacity for future offerings.

Pyxis Oncology (NASDAQ:PYXS) raised $110M from a public offering, selling 36M shares at $2.90 each and warrants. Additional proceeds of $172.6M could be raised if milestone-linked warrants are exercised. Proceeds will fund clinical trials and general corporate purposes, with data updates expected in 2026-2027.

Pyxis Oncology (PYXS) closed a public offering, raising $110M upfront. The deal includes milestone-linked warrants that could add $172.6M if exercised, totaling $282.6M. Proceeds will fund clinical trials, including MICVO for head and neck cancer, and general corporate purposes. The offering involved new and existing institutional investors.

Pyxis Oncology (PYXS) raised $102.8M in a public offering of common stock and warrants, priced at $2.90 per share. The offering was led by Leerink, Guggenheim, and Wells Fargo. Proceeds will support clinical development and corporate needs, including the Phase 3 Headliner trial.

Pyxis Oncology (PYXS) priced a public offering for $110M, leading to an 8.8% drop in after-hours trading to $2.64. The offering includes 36.05M shares.